Nurix Therapeutics Inc (NRIX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Nurix Therapeutics Inc stock (NRIX) is currently trading at $15.44. Nurix Therapeutics Inc PS ratio (Price-to-Sales) is 17.67. Analyst consensus price target for NRIX is $30.00. WallStSmart rates NRIX as Sell.
- NRIX PE ratio analysis and historical PE chart
- NRIX PS ratio (Price-to-Sales) history and trend
- NRIX intrinsic value — DCF, Graham Number, EPV models
- NRIX stock price prediction 2025 2026 2027 2028 2029 2030
- NRIX fair value vs current price
- NRIX insider transactions and insider buying
- Is NRIX undervalued or overvalued?
- Nurix Therapeutics Inc financial analysis — revenue, earnings, cash flow
- NRIX Piotroski F-Score and Altman Z-Score
- NRIX analyst price target and Smart Rating
Nurix Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Nurix Therapeutics Inc (NRIX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Nurix Therapeutics Inc (NRIX) Key Strengths (1)
111.36% of shares held by major funds and institutions
Supporting Valuation Data
Nurix Therapeutics Inc (NRIX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 17.7x annual revenue
Revenue growing slowly at 2.20% annually
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Nurix Therapeutics Inc (NRIX) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (17.67), Price/Book (2.75) suggest expensive pricing. Growth concerns include Revenue Growth at 2.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -49.60%, Operating Margin at -612.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -49.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NRIX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NRIX's Price-to-Sales ratio of 17.67x trades at a deep discount to its historical average of 58.75x (11th percentile). The current valuation is 92% below its historical high of 209.96x set in Jan 2021, and 68% above its historical low of 10.5x in Jan 2024. Over the past 12 months, the PS ratio has compressed from ~22.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Nurix Therapeutics Inc (NRIX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Nurix Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 84M with 220% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 220% YoY, reaching 84M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 96% of revenue (81M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -73M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Nurix Therapeutics Inc maintain 220%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.02, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Nurix Therapeutics Inc.
Bottom Line
Nurix Therapeutics Inc is a high-conviction growth story with revenue accelerating at 220% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(44 last 3 months)
| Insider | Type | Shares |
|---|---|---|
RING, CHRISTINE Chief Legal Officer | Sell | -8,148 |
| Insider | Type | Shares |
|---|---|---|
RING, CHRISTINE Chief Legal Officer | Sell | -14,261 |
Data sourced from SEC Form 4 filings
Last updated: 8:26:09 AM
About Nurix Therapeutics Inc(NRIX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.